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Abstract
DLL4 is a ligand for the Notch family of receptors. DLL4 has many important functions in normal development and
tissue homeostasis, including roles in the immune system, the gastro-intestinal tract, and in vascular development.
Because of the importance of Notch signaling in stem cell biology, DLL4 has been investigated for its role in the
maintenance and proliferation of cancer stem cells (CSC). In addition, its important role in angiogenesis has been
investigated for utility as an anti-angiogenic agent. Preclinical studies have highlighted that both anti-CSC and anti-
angiogenic activities contribute to its anti-tumor efficacy, and have supported the clinical development of anti-
DLL4 antibody for the treatment of cancer.
Introduction
Cancer can be considered as an aberrant and mutant
recapitulation of normal tissue development and home-
ostasis. Tumors are typically highly heterogeneous at the
cellular level, and this heterogeneity frequently mirrors
the cellular heterogeneity of the normal tissue. Normal
tissue development and homeostasis is driven by an
organized hierarchy of stem and progenitor populations
which give rise to various differentiated cell types with
specialized functions. Long term tissue maintenance is
enabled by the unique ability of the stem cell to exhibit
self-renewal, which is defined as the ability to proliferate
while maintaining pluripotency. Similarly, cancer cells
inappropriately activate self-renewal pathways and this
enables their ability to grow indefinitely. Thus, the
potential connections between normal stem cells and
cancer have great importance for understanding tumor
biology and also for developing new therapeutic strate-
gies. In the past decade it has become increasingly clear
that this self-renewal property is not possessed by all
cells within a tumor, but that there exists a subpopula-
tion of cells, often referred to as “cancer stem cells” or
“tumor initiating cells” which possesses the ability to
undergo self-renewal and thereby drive the growth of
the tumor [1-3]. These cells also possess the ability to
initiate the growth of new tumors that recapitulate the
heterogeneity of the parent tumor. Thus, these cells
have hallmark capabilities analogous to normal stem
cells. This relationship has been strengthened by genetic
studies which have shown that normal stem cells can be
the cell of origin for tumors [4]. Additionally, cancer
initiating mutations can originate in more differentiated
cells and confer stem-like properties on the tumor cells.
These connections have led to a careful examination of
stem cell signaling pathways and their role in cancer.
Intriguingly, several of these pathways, including the
Notch and Wnt pathways, have long been recognized to
be activated by oncogenic mutations and disregulated in
cancer.
In addition to cancer’s need to achieve the stem cell-
like property of self-renewal, a cancer must also recruit
a support system of stroma and vasculature. The devel-
opment of vasculature is a complex developmental pro-
cess, analogous to the development of organs, and so it
is not surprising to note that here too signaling path-
ways important to stem cells, including Notch, have
important role in cell fate decisions. There are roles
recognized for multiple Notch receptors and multiple
Notch ligands within this process [5-8]. These molecules
play roles both within the endothelial cell layer, where
they are involved in vessel branching and maturation,
and in the surrounding pericyte and smooth muscle
layers. Jagged1 and Notch3 are of particular importance
in pericyte function [9-11]. DLL4 acting through Notch1
and Notch4 appears to play key roles regulating
endothelial cells and bone marrow-derived endothelial * Correspondence: austin.gurney@oncomed.com
OncoMed Pharmaceuticals, 800 Chesapeake Drive, Redwood City, California
94063, USA
Gurney and Hoey Vascular Cell 2011, 3:18
http://www.vascularcell.com/content/3/1/18 VASCULAR CELL
© 2011 Gurney and Hoey; licensee BioMed Central Ltd. This is an Open Access article distributed under the terms of the Creative
Commons Attribution License (http://creativecommons.org/licenses/by/2.0), which permits unrestricted use, distribution, and
reproduction in any medium, provided the original work is properly cited.cell progenitors during normal and tumor angiogenesis
[12,13].
These two lines of research, the role of the Notch
pathway in the maintenance of cancer stem cells, and
the activity of Notch in tumor vasculature, have led to
intense research interest in targeting components of this
pathway for the development of novel therapeutics.
Through this effort, DLL4 has emerged as a compelling
target. Indeed, an antibody to DLL4, OMP-21M18, was
the first therapeutic entity that selectively targeted the
Notch pathway to enter human clinical trials. Gamma-
secretase inhibitors (GSIs) that inhibit the ligand-depen-
dent cleavage of Notch receptors have also been devel-
oped as anti-cancer therapies. Treatment with GSIs has
been found to result in severe gastrointestinal toxicity,
limiting their therapeutic utility, due to the combined
inhibition of both Notch1 and Notch2 within the stem-
progenitor compartment of the intestinal crypt [14,15].
In addition to processing Notch proteins, gamma-secre-
tase cleaves many other membrane proteins and is
involved in a large number of signaling pathways apart
from Notch, and these pleiotropic effects are also likely
to contribute to the toxicity of GSIs [16,17].
DLL4 is one of three delta-like ligands in the mamma-
lian genome [18]. Similar to Drosophila Delta, it acts as
an agonist ligand to modulate the activity of Notch
receptors. Binding studies and in vitro signal transduc-
tion studies indicate that DLL4 is readily able to signal
through each of the four human Notch receptors,
demonstrating its potential to participate in many of the
diverse functions that have been described for the
Notch family. Elucidating the full range of its activities
is an ongoing area of investigation, and is somewhat
complicated by the potential for compensatory action by
other Notch ligands. Further complicating this analysis
is the potential for DLL4 to be expressed in minor sub-
sets of cells, such as stem cells and progenitors, which
may lead to an under-appreciation of DLL4 expression
and its relevance to a particular tissue. LacZ reporter
studies in developing mouse embryos have revealed
expression with the vascular system, multiple structures
within the nervous system, the gastrointestinal system,
the glomeruli of the kidney, and the thymus [19] Gene
disruption studies indicate that DLL4 plays an important
role in angiogenesis - haploinsufficiency results in
embryonic lethality due to angiogenic defects [20-22].
Conditional gene disruption studies have also demon-
strated critical roles for DLL4 in T cell development
[23,24]. In addition, DLL4 is also expressed by myeloid
cells including macrophage and dendritic cells and plays
a role in modulating adaptive immune response [25-27].
DLL4 is one of the ligands important for lineage com-
mitment within the epithelial cell lining of the gastroin-
testinal tract. Interestingly, DLL1 and DLL4 appear to
have redundant functions in normal intestinal develop-
ment and homeostasis [28], which accounts for the fact
that selective inhibition of DLL4 has minimal impact on
the function of the GI tract.
Mechanism of DLL4 in Angiogenesis
Several groups have reported the discovery of antibodies
which block the ability of DLL4 to activate Notch
[29-31]. This work contributed to the discovery that
DLL4-Notch signaling is part of a negative feedback
loop in the angiogenic process. Blockade of DLL4-Notch
binding or loss of function of DLL4 leads to an up-regu-
lation of VEGF signaling resulting in deregulated, hyper-
proliferation of the tip cells ultimately leading to
immature vessels that lack a functional lumen. It has
been shown that DLL4 inhibition can have a widespread
effect in reducing tumor growth in a number of differ-
ent xenograft models through this angiogenic mechan-
ism [29,30]. Inhibition of VEGF signaling is now a well
established strategy for anti-cancer therapeutics [32,33].
T h ew o r ko nD L L 4s h o w st h a tu p - r e g u l a t i o no fV E G F
in tumor vasculature can also have a therapeutic benefit.
Tumors responsive to anti-DLL4 include those that are
resistant to inhibition with anti-VEGF highlighting the
potential utility of this approach.
We now have a fairly detailed understanding of the
mechanism of action for how disrupting DLL4-Notch
signaling leads to non-functional vasculature and
thereby reduces tumor growth. Normally, DLL4-Notch
signaling restricts the numbers of tip cells in response
to VEGF, whereas inhibition of DLL4 leads to increased
tip cell formation and reduced numbers of stalk cells in
angiogenic regions [34]. Inhibition of DLL4 up-regulates
VEGF expression as well as its receptors VEGFR2 and
VEGFR3. The effect of DLL4 on sprouting angiogenesis
is also mediated through regulation of matrix metallo-
proteinase (MMP) expression [35].
Role of DLL4 in Tumor Initiating Cells
In addition to its role in the tumor vasculature, evidence
has accumulated indicating an important role for DLL4-
Notch signaling in tumor cells [36,37]. Across a range of
major tumor types, including colorectal, kidney, breast
and lung cancer, DLL4 protein expressed by tumor cells
can be detected in a high percentage of patient samples
[38]. An anti-DLL4 antibody, OMP-21M18, was found
to have anti-tumor activity in patient-derived xenograft
models independent of any effect on angiogenesis [27].
This antibody does not cross-react with murine DLL4
and therefore has no effect on the vasculature in murine
xenografts. The combination of blocking DLL4 in tumor
and vascular cells was shown to have an additive effect.
Importantly, inhibition of DLL4 not only reduced tumor
growth but also reduced tumor initiating cells as shown
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colon tumors with anti-DLL4 up-regulates markers of
more differentiated colon cells (for example, ATOH1
and Chromogranin A) indicating that DLL4-Notch inhi-
bition limits the stem/progenitor-like properties of
colon tumor cells and promotes a more differentiated
phenotype. Potential insight into how DLL4-Notch
signaling might function in colon cancer is provided by
the fact that in normal colon development DLL4 is
expressed on the paneth cells [39] which are adjacent to
the stem cells and thought to play an important role as
the niche to support stem cell maintenance and self-
renewal through activation of Notch signaling.
Anti-DLL4 treatment was shown to have synergistic
activity with various chemotherapeutic agents in redu-
cing tumor volume and tumor initiating cell frequency
[31]. These data are consistent with the hypothesis that
the less differentiated, stem-like cancer cells are resistant
to conventional cancer treatments including chemother-
apy whereas promoting differentiation sensitizes tumor
cells to the cytotoxic effects of chemotherapeutic drugs.
More recently, anti-DLL4 was found to be active in a
number of colon tumor xenografts including those har-
boring KRAS mutations which are insensitive to anti-
EGFR treatment [40]. Since tumorigenic CSCs are
thought to mediate tumor recurrence after treatment
and the metastatic spread of the disease, agents that
block key CSC self-renewal hold tremendous promise as
improved cancer treatments.
Perspective
Anti-DLL4 attacks cancers through two distinct
mechanisms, an anti-angiogenic effect and a reduction
of CSCs, each fundamental for malignant tumor growth.
This target offers tremendous potential for improved
efficacy in cancer treatment. As discussed above, inhibi-
tion of DLL4 signaling has been shown to result
endothelial cell hyperproliferation and increased vascular
sprouting in tumor angiogenesis. In rodents, DLL4 inhi-
bition or loss of function has been associated with cer-
tain adverse events including vascular hyperproliferation
in the liver and non-malignant vascular neoplasms
[41,42]. These data raise concerns about potential toxici-
ties associated with anti-DLL4 therapy in the clinic
linked to its mechanisms of action in the vasculature
and/or in stem cell biology. At least two anti-DLL4 anti-
bodies have entered clinical testing (OMP-21M18 from
OncoMed and REGN421 from Regeneron). To date
there have not been reported incidents of either liver
toxicity or vascular neoplasms in these clinical pro-
grams. None-the-less, DLL4 is an important ligand
within a fundamental signaling pathway, and a molecule
that robustly impacts vascular development, so it would
not be surprising if adverse consequences to DLL4
inhibition are observed during clinical testing. Ongoing
clinical studies will determine if this approach in block-
ing DLL4 can be developed into an effective therapeutic.
As with all cancer therapeutics, identifying the right dis-
ease setting, dosing regimen, and combination strategy
will be critical for successful drug development. It has
been nearly 25 years since Notch was implicated in can-
cer by the discovery of Notch4/int-3 as a mammary
proto-oncogene following activation by mouse mam-
mary tumor virus (MMTV) integration [43,44]. With
our increasing understanding of the function of this
pathway in both normal cell fate decisions and in can-
cer, anti-DLL4 may become the prototype member of a
new class of therapeutic agents.
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